Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival

Table 4 Clinical characteristics and frequency of each type of immune-related adverse event in patients with non-small cell lung carcinoma and malignant melanoma

Characteristic	NSCLC, n = 209	MM, n = 130
Age, yr	66 ± 11	66 ± 13
Sex, n (%)
Male	143 (68.4)	75 (57.7)
Female	66 (31.6)	55 (42.3)
BMI, kg/m2	21.7 ± 3.4	22.4 ± 4.3
ECOG PS, n
0-1	184	119
2-3	25	11
Drugs, n (%)
Nivolumab	61 (29.2)	58 (44.6)
Pembrolizumab	87 (41.6)	35 (26.9)
Atezolizumab	61 (29.2)	0 (0.0)
Ipilimumab	0 (0.0)	27 (20.8)
Nivolumab + ipilimumab	0 (0.0)	10 (7.7)
History of ICI use, n (%)	11 (5.3)	34 (26.2)
Follow-up, d	365 ± 335	466 ± 419
Total irAEs, n (%)
GI-irAEs	9 (4.3)	13 (10.0)
Liver-irAEs	7 (3.3)	13 (10.0)
Lung-irAEs	10 (4.8)	11 (8.5)
Skin-irAEs	9 (4.3)	9 (6.9)
Thyroid-irAEs	12 (5.7)	9 (6.9)

BMI: Body mass index; ECOG PS: Eastern Cooperative Oncology Group performance status; GI: Gastrointestinal; irAE: Immune-related adverse event; ICI: Immune checkpoint inhibitor; MM: Malignant melanoma; NSCLC: Non-small cell lung carcinoma.